Merck closed the most recent trading day at $144.71, down 1.91% from the previous session, a steeper decline than the S&P 500's 0.59% loss, while the Dow fell 0.6% and the Nasdaq dropped 0.65%. Ahead of Merck's upcoming financial release, analysts expect earnings of $2.27 per share, a year-over-year decline of 12.02%, on revenue of $17.61 billion, up 1.94% from the same quarter a year earlier. For the full year, the Zacks Consensus Estimates project earnings of $2.97 per share and revenue of $67.25 billion, changes of -66.93% and +3.45% respectively from last year. Over the past month the Zacks Consensus EPS estimate has moved 0.38% lower, and Merck currently carries a Zacks Rank #3 (Hold). The stock trades at a Forward P/E of 49.6 versus an industry average of 15.55, with a PEG ratio of 5.97 against the Large Cap Pharmaceuticals industry average of 2.01.
Merck & Company IncAnalysts expect Merck's upcoming earnings to fall 12.02% YoY and full-year EPS to drop 66.93%, with the consensus estimate revised lower over the past month.
Merck KGaA